Safety and tolerability of B1344 injections for NAFLD
Part of Digestive system clinical trials.
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and Chinese
- You have NAFLD with a liver fat level of at least 10% on an MRI scan
- You have at least one metabolic risk factor like being overweight, having high blood sugar, high blood pressure, or abnormal blood fats
- Your weight has been stable (no more than 5% change) in the last 6 weeks
- You agree to use effective birth control during the trial and for 3 months after
- You do not have cirrhosis, other liver diseases, or certain other serious health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.
This Phase 2 trial tests whether namodenoson can improve non-alcoholic steatohepatitis (NASH), a type of fatty liver inflammation. You may need two liver biopsies to see whether liver changes improve over time.
This study follows adults with nonalcohol-related fatty liver disease (NAFLD) to better understand the condition and what factors affect it. It may help researchers learn which patients are most at risk and how care can be improved in the future.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.
Hear when a new NASH - Nonalcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.